To see the other types of publications on this topic, follow the link: Biotechnology business.

Journal articles on the topic 'Biotechnology business'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Biotechnology business.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mannion, Antoinette M. "Biodiversity, Biotechnology, and Business." Environmental Conservation 22, no. 3 (1995): 201–10. http://dx.doi.org/10.1017/s0376892900010596.

Full text
Abstract:
Biotechnology is probably the only industry, except agriculture, wherein the relationship between biodiversity and the wealth that it generates is so explicit. Biodiversity is the variety of organisms, their genetic variation, and the variability of associations that these organisms display spatially. Biotechnology is the harnessing of living organisms and/or their components to undertake specific processes and/or generate useful products. The modern industry is a product of the 1980s and relies heavily on genetic manipulation (commonly referred to as ‘engineering’). It has many applications,
APA, Harvard, Vancouver, ISO, and other styles
2

Demain, Arnold L. "REVIEWS: The business of biotechnology." Industrial Biotechnology 3, no. 3 (2007): 269–83. http://dx.doi.org/10.1089/ind.2007.3.269.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hybels, Ralph C., and Maureen McKelvey. "Evolutionary Innovations: The Business of Biotechnology." Administrative Science Quarterly 43, no. 4 (1998): 961. http://dx.doi.org/10.2307/2393629.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Galambos, Louis, Jeffrey L. Sturchio, and Maureen D. McKelvey. "Evolutionary Innovations: The Business of Biotechnology." Technology and Culture 39, no. 2 (1998): 332. http://dx.doi.org/10.2307/3107066.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Francisco, Michael. "Websites for the business of biotechnology." Nature Biotechnology 16, no. 6 (1998): 590. http://dx.doi.org/10.1038/nbt0698-590.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

O'SULLIVAN, DERMOT. "ICI to expand its biotechnology business." Chemical & Engineering News 67, no. 7 (1989): 38. http://dx.doi.org/10.1021/cen-v067n007.p038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Norris, Charles E. "Tax and the business of biotechnology." Trends in Biotechnology 4, no. 7 (1986): 169–72. http://dx.doi.org/10.1016/0167-7799(86)90240-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rhyne, Lawrence C. "Business model design for biotechnology firms." International Journal of Business Innovation and Research 3, no. 3 (2009): 298. http://dx.doi.org/10.1504/ijbir.2009.024181.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Schachter, Beth. "Slimy business—the biotechnology of biofilms." Nature Biotechnology 21, no. 4 (2003): 361–65. http://dx.doi.org/10.1038/nbt0403-361.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gressel, Jonathan. "Best Practices in Biotechnology Business Development." Journal of Commercial Biotechnology 14, no. 4 (2008): 365–67. http://dx.doi.org/10.1057/jcb.2008.27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Konde, Viren. "Biotechnology business models: An Indian perspective." Journal of Commercial Biotechnology 15, no. 3 (2008): 215–26. http://dx.doi.org/10.1057/jcb.2008.52.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Greiner, Raphael, and Siah Hwee Ang. "Biotechnology collaborations: does business model matter?" Journal of Management & Governance 16, no. 3 (2010): 377–92. http://dx.doi.org/10.1007/s10997-010-9156-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Vilmantas, Vaidas, and Borisas Melnikas. "Advancement of Marketing Developing Biotechnology-Based Business." Verslas: teorija ir praktika 15, no. 3 (2014): 210–19. http://dx.doi.org/10.3846/btp.2014.21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

BAUM, RUDY M. "Two Critics Look at the Biotechnology Business." Chemical & Engineering News 64, no. 5 (1986): 32–34. http://dx.doi.org/10.1021/cen-v064n005.p032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Daly, Peter. "{BLR 438} BLR BIBLIOGRAPHY: Book - Biotechnology Business." Biotechnology Law Report 4, no. 10 (1985): 315. http://dx.doi.org/10.1089/blr.1985.4.315.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Spiro, Howard. "The gene business: Who should control biotechnology?" Gastroenterology 93, no. 2 (1987): 400. http://dx.doi.org/10.1016/0016-5085(87)91040-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Vilmantas, Vaidas, and Borisas Melnikas. "Advancement of Marketing Developing Biotechnology-Based Business." Business: Theory and Practice 15, no. (3) (2014): 210–19. https://doi.org/10.3846/btp.2014.21.

Full text
Abstract:
The article, in a complex way, analyzes the needs of marketing improvement in developing biotechnology­based business and highlights its role in the context of modern society and globalization challenges. The article distinguishes between the existing problems of biotechnology business, the present perspectives and specific characteristics of developing the marketing of biotechnological business. The paper represents the possibility of the substantial modernization of marketing tools with regard to modelling user's behaviour, improvement in marketing strategy for the company, the correction of
APA, Harvard, Vancouver, ISO, and other styles
18

Будякова, Олена, and Діана Пригарська. "Opportunities for implementing the bioeconomy in the pharmaceutical business." Food Industry Economics 16, no. 2 (2024): 52–58. http://dx.doi.org/10.15673/fie.v16i2.2941.

Full text
Abstract:
This study examines the bioeconomy’s role in the pharmaceutical sector, emphasizing biotechnology’s impact and forecasts for biological products up to 2028. It highlights growth trends and significance, alongside employment and productivity metrics in 2015 and 2020. A case study on Gilead Sciences illustrates how biotechnology influences its growth, and a flowchart outlines future bioeconomy development. The bioeconomy utilizes biological resources to create products that enhance environmental sustainability and human health. The dynamic pharmaceutical industry, focused on medication research
APA, Harvard, Vancouver, ISO, and other styles
19

V Mangrulkar, Shubhada, Shailju G. Gurunani, Dhanashri T. Jawal, and Dinesh R Chaple. "Bioentrepreneurship: A venture for commercializing biotechnological knowledge." IP International Journal of Comprehensive and Advanced Pharmacology 6, no. 2 (2021): 48–52. http://dx.doi.org/10.18231/j.ijcaap.2021.009.

Full text
Abstract:
The term "biotechnology" is widely used and encompasses many different technologies. Consulting firms provide common definitions of modern biotechnology. The term "modern biotechnology" refers to all innovative methods, processes or products, including the use of living organisms or their cellular compartments, and the use of biochemistry, molecular biology, immunology, virology, microbiology, cell biology or environmental sciences and engineering. Biotechnology and entrepreneurship are intrinsically linked together, and are studied biotechnology at the regional, firm, and individual level of
APA, Harvard, Vancouver, ISO, and other styles
20

Wertheimer, Albert I., and Sondra Grumer. "Therapeutic Applications and Economic Opportunities in the Biotechnologic Pharmaceutical Industry." Journal of Pharmacy Technology 9, no. 6 (1993): 249–53. http://dx.doi.org/10.1177/875512259300900605.

Full text
Abstract:
Objective To discuss the expected future development and implications of the US biotechnologic pharmaceutical industry. Foreign competition and internal forces that might impede the industry are also discussed. Data Sources Searches were conducted in the Business Periodicals Index and the International Pharmaceutical Abstracts databases. Study Selection All studies pertaining to the business of biotechnology were reviewed. Conclusions Biotechnologically produced agents will require a shorter period of development and a less costly production process, and will be generally safer than convention
APA, Harvard, Vancouver, ISO, and other styles
21

Conway, Clifford. "Nanotechnogy and Biotechnology: Enterprising Futures." International Journal of Entrepreneurship and Innovation 9, no. 1 (2008): 69–70. http://dx.doi.org/10.5367/000000008783563000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Dubovyi, Georgii. "Georgii Dubovyi: Innovations in Biotechnology and their Impact on Business." Universal Library of Business and Economics 02, no. 02 (2025): 22–24. https://doi.org/10.70315/uloap.ulbec.2025.0202006.

Full text
Abstract:
This article examines innovations in biotechnology and their impact on business, covering key areas such as medicine, agriculture, ecology and industry. The purpose of the study is to analyze the importance of biotechnology for creating new products and services, increasing the efficiency of production processes and improving the quality of life. The main objectives include studying the role of biopharmaceuticals, genetically modified organisms, bioplastics and biocatalysts in various sectors of the economy. The results show that innovations in biotechnology not only contribute to economic gro
APA, Harvard, Vancouver, ISO, and other styles
23

Feeney, Roberto, Carlos Perez, and Pablo Mac Clay. "Bioceres: AG Biotechnology from Argentina." International Journal on Food System Dynamics 7, no. 2 (2016): 92–115. https://doi.org/10.18461/ijfsd.v7i2.724.

Full text
Abstract:
In this case we present a business decision-making situation in which the CEO of an Argentine Ag Biotech company, Bioceres, has to decide the best way to commercialize a new drought-tolerant transgenic technology. The company was founded by twenty three farmers, who shared a common dream that Argentina could become a benchmark in the development of Ag biotechnology. The case has strategic and financial implications, as well as decision-making situation involving a joint venture with an American biotechnology company. It also introduces to discussion the business models of Ag biotechnology comp
APA, Harvard, Vancouver, ISO, and other styles
24

Walker, Larry. "Industrial Biotechnology and IB Get Down to Business." Industrial Biotechnology 9, no. 2 (2013): 51–52. http://dx.doi.org/10.1089/ind.2013.1567.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

March-Chordà, Isidre, Rosa M. Yagüe-Perales, and Ramón Seoane-Trigo. "Asymmetric behaviour of biotechnology business patterns in Spain." Technology Analysis & Strategic Management 21, no. 6 (2009): 765–82. http://dx.doi.org/10.1080/09537320903052780.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Gupta, Anil K., and Vikas Chandak. "Agricultural biotechnology in India: ethics, business and politics." International Journal of Biotechnology 7, no. 1/2/3 (2005): 212. http://dx.doi.org/10.1504/ijbt.2005.006455.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Dibner, Mark D., and Cynthia J. Sollod. "From bench to business: Career opportunities in biotechnology." Nature Biotechnology 15, no. 10 (1997): 958–60. http://dx.doi.org/10.1038/nbt1097-958.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Kind, Sonja, and Dodo zu Knyphausen-Aufseß. "What is “Business Development”? — The Case of Biotechnology." Schmalenbach Business Review 59, no. 2 (2007): 176–99. http://dx.doi.org/10.1007/bf03396747.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Giedraitis, Vincentas R., Tom Notten, and Aušra Rastenienė. "BUSINESS CLUSTERS AND THE POTENTIAL OF THE BIOTECHNOLOGY SECTOR IN LITHUANIA." Ekonomika 87 (January 1, 2009): 81–89. http://dx.doi.org/10.15388/ekon.2009.0.1044.

Full text
Abstract:
What are the unique circumstances that allow innovations in an economy to take hold and mature into productive business sectors? We pose the given question in our discussion of the uncommonly favorable circumstances surrounding the biotechnology sector in Lithuania. The purpose of this paper is to analyze Lithuania’s ability to expand its economy during a time of crisis, focusing on its unique ability to innovate in such sectors as biotechnology.Our primary hypothesis is as follows: Lithuanian biotechnology sector is expanding because business clusters have been established. Drawing upon Schum
APA, Harvard, Vancouver, ISO, and other styles
30

He, Yongyan. "Analysis of the Impact of Innovation Subsidy Policy on Biological Enterprises." Advances in Economics, Management and Political Sciences 98, no. 1 (2024): 151–58. http://dx.doi.org/10.54254/2754-1169/98/2024ox0190.

Full text
Abstract:
BASF, one of the world's leading chemical enterprises, has been actively engaged in biotechnology in recent years, committed to integrating biotechnology with traditional chemical technology and promoting the development of sustainable solutions. This report aims to analyze BASF's financial statements for 2021, 2022, and others to evaluate the performance of its biotechnology business in four key aspects: solvency, upstream and downstream competition, profitability, and operating capacity, to provide a reference for corporate decision-makers and investors. According to the public information,
APA, Harvard, Vancouver, ISO, and other styles
31

Strauss, Harlee. "Behind Biotechnology The Gene Factory: Inside the Genetic and Biotechnology Business Revolution John Elkington." BioScience 37, no. 4 (1987): 284–85. http://dx.doi.org/10.2307/1310592.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Demicheli, Mario C. "Realizing the Potential of Agricultural Biotechnology in Europe." Outlook on Agriculture 26, no. 2 (1997): 79–85. http://dx.doi.org/10.1177/003072709702600204.

Full text
Abstract:
Set for success in the market, biotechnology could fulfil several objectives of the European Union, notably those relating to health, agriculture, the environment, technological development and general business competitiveness. However, several factors hinderthis knowledge-based technology from realizing its potential in Europe, as is measured by the usual indicators of competitiveness. The reasons are examined through a bottom-up approach, starting from the management of biotechnology research and moving towards business strategy and the role of consumers and regulators. Agricultural biotechn
APA, Harvard, Vancouver, ISO, and other styles
33

Krimsky, Sheldon. "The Gene Business. Who Should Control Biotechnology?Edward Yoxen." Quarterly Review of Biology 60, no. 1 (1985): 74–75. http://dx.doi.org/10.1086/414205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Groote, Joyce, and Barry Gee. "British Columbia's biotechnology industry: blending research, business and lifestyle." Drug Discovery Today 10, no. 12 (2005): 816–19. http://dx.doi.org/10.1016/s1359-6446(05)03476-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Bigliardi, Barbara, Anna Nosella, and Chiara Verbano. "Business models in Italian biotechnology industry: a quantitative analysis." Technovation 25, no. 11 (2005): 1299–306. http://dx.doi.org/10.1016/j.technovation.2004.10.013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

NIKULAINEN, TUOMO, RAINE HERMANS, and MARTTI KULVIK. "PATENT CITATIONS INDICATING PRESENT VALUE OF THE BIOTECHNOLOGY BUSINESS." International Journal of Innovation and Technology Management 05, no. 03 (2008): 279–301. http://dx.doi.org/10.1142/s0219877008001436.

Full text
Abstract:
In this paper our aim is to assess the potential of using patent statistics in predicting the future sales anticipations and present value of a company active in the science-based industry. Instead of using conventional patent and patent application counts as indicators, we constructed patent citation weighted portfolios for each company. This way the heterogeneity of patents can be taken into account. Our data covers biotechnology patents held by Finnish biotechnology companies. Empirical results imply that particularly backward citations are related to present value estimations of the compan
APA, Harvard, Vancouver, ISO, and other styles
37

Glick, J. Leslie. "Biotechnology business models work: Evidence from the pharmaceutical marketplace." Journal of Commercial Biotechnology 14, no. 2 (2008): 106–17. http://dx.doi.org/10.1057/palgrave.jcb.3050085.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Efremidze, Levan. "Innovation, Business Strategies and Stock Returns in Biotechnology Industry." International Journal of Financial Research 14, no. 1 (2023): 71. http://dx.doi.org/10.5430/ijfr.v14n1p71.

Full text
Abstract:
The paper analyzes the impact of small biotechnology firms' innovation and business strategies on their stock returns utilizing event study methodology. These are some of the conclusions supported by the empirical results: (i) firms should focus on regulatory approval of their products; (ii) it is important to recruit individuals and consulting firms with valuable specialized expertise in field; (iii) firms should pursue licensing and manufacturing deals aggressively; and (iv) firms should be highly selective and careful with deals they make for R&D collaboration with scientific community.
APA, Harvard, Vancouver, ISO, and other styles
39

Chisti, Yusuf. "Fraudulent business..." Biotechnology Advances 39 (March 2020): 107483. http://dx.doi.org/10.1016/j.biotechadv.2019.107483.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Martínez Pantoja, Yadira Ixchel. "Business Diplomacy Strategies and Instruments: Biotechnology Companies Promoting GMOs in Mexico." Hague Journal of Diplomacy 13, no. 4 (2018): 457–82. http://dx.doi.org/10.1163/1871191x-13040000.

Full text
Abstract:
Summary Business diplomacy emphasizes engagement with stakeholders to shape the environment to favour business interests. This article recognizes that multinational corporations (MNCs) play a relevant role in the international arena, dealing with governments and other non-state actors by means of business diplomacy. Biotechnology companies, in particular, bargain with government representatives for commercialization, deregulation or intellectual property enforcement. In order to advance their economic and business goals, biotechnology companies have implemented reactive, proactive and relation
APA, Harvard, Vancouver, ISO, and other styles
41

Meyer, Hans-Peter, and Oleg Werbitzky. "Development of Swiss Biotechnology Beyond the Biopharmaceutical Sector In memoriam Prof. Dr. Oreste Ghisalba (1946–2018)." CHIMIA International Journal for Chemistry 74, no. 5 (2020): 345–59. http://dx.doi.org/10.2533/chimia.2020.345.

Full text
Abstract:
Although diverse, the potential business opportunities for biotechnology outside the biopharmaceutical market are very large. White biotechnology can offer sustainable operations and products, while investments tend to be lower than those in red biotechnology. But a number of bottlenecks and roadblocks in Switzerland must be removed to realise the full potential of white biotechnology. This was also the point of view of Oreste Ghisalba, who wanted to be part of a new initiative to facilitate the creation of additional business, new processes and new products. This initiative requires the ident
APA, Harvard, Vancouver, ISO, and other styles
42

Archie, Sultan Eka Buana, and Ratnaningtyas Sudrajati. "The Impact of Biotechnology Product Innovation and Corporate Strategy in Medium-Scale Seaweed Industry Companies on the Company Business Growth (Case Study: Ocean Fresh CV)." International Journal of Current Science Research and Review 06, no. 01 (2023): 523–34. https://doi.org/10.5281/zenodo.7565732.

Full text
Abstract:
<strong>ABSTRACT: </strong>A product innovation approach that can have a positive impact on both the environment and consumers is biotechnology. Seaweed, a material obtained from the sea, offers a lot of potential. Future prospects for several industries include the use of seaweed product innovation employing a biotechnology method. This research is based on business issues and how to maximize existing potential. This research aims to study the performance of the corporate strategy and the development of product innovation in a biotechnology-based company, namely Ocean Fresh CV. Data collectio
APA, Harvard, Vancouver, ISO, and other styles
43

Daniel S. Levine. "From Breakthrough to Blockbuster: A conversation with Donald Drakeman." Journal of Commercial Biotechnology 27, no. 2 (2022): 1–4. http://dx.doi.org/10.5912/jcb1266.

Full text
Abstract:
In their new book From Breakthrough to Blockbuster: The Business of Biotechnology, Donald Drakeman, Lisa Drakeman, and Nektarios Oraiopoulos revisit a question posed by Harvard Business School Professor Gary Pisano about the ability of small, entrepreneurial biotechnology companies to compete against large pharmaceutical companies in a research-driven, capital-intensive, and highly regulated industry. While Pisano in his 2006 book Science Business: The Promise, the Reality, and the Future of Biotech found biotech had failed to live up to its promise and that large pharmaceutical companies shou
APA, Harvard, Vancouver, ISO, and other styles
44

Esposito, Robert S., and Marc J. Ostro. "Strategic consolidation: The biotechnology business model for the 21st century." Nature Biotechnology 17, S1 (1999): BE16—BE17. http://dx.doi.org/10.1038/4630.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

THAYER, ANN. "BUSINESS INSIGHTS Market for biotechnology stocks: continued lull or turnaround?" Chemical & Engineering News 72, no. 31 (1994): 24. http://dx.doi.org/10.1021/cen-v072n031.p024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Wagner, Cynthia K. "Biotechnology in Mexico: placing science in the service of business." Technology in Society 20, no. 1 (1998): 61–73. http://dx.doi.org/10.1016/s0160-791x(97)00028-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Dibner, Mark D. "Finding what you need to know in the biotechnology business." Trends in Biotechnology 12, no. 1 (1994): 1–2. http://dx.doi.org/10.1016/0167-7799(94)90002-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Vaara, Eero. "Strategic Alliances as Social Facts: Business, Biotechnology and Intellectual History." Journal of International Business Studies 35, no. 1 (2003): 75–77. http://dx.doi.org/10.1057/palgrave.jibs.8400063.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Persidis, Aris, and Francesco De Rubertis. "Spin-offs versus start-ups as business models in biotechnology." Nature Biotechnology 18, no. 5 (2000): 570–71. http://dx.doi.org/10.1038/75476.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Davies, Gail. "The funny business of biotechnology: Better living through chemistry comedy." Geoforum 38, no. 2 (2007): 221–23. http://dx.doi.org/10.1016/j.geoforum.2006.09.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!